Scarica l'app Stockscreener
8.65
27.02%
1.84
Dopo l'orario di chiusura:
8.51
-0.14
-1.62%
Precedente Chiudi:
$6.81
Aprire:
$7.15
Volume 24 ore:
669.36K
Relative Volume:
8.71
Capitalizzazione di mercato:
$138.57M
Reddito:
-
Utile/perdita netta:
$-14.72M
Rapporto P/E:
-3.0565
EPS:
-2.83
Flusso di cassa netto:
$-7.41M
1 W Prestazione:
+16.42%
1M Prestazione:
+103.53%
6M Prestazione:
+61.09%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$6.95
$9.68
Intervallo di 1 settimana:
$6.55
$9.68
Portata 52W:
$3.75
$9.68
Alpha Cognition Inc Stock (ACOG) Company Profile
Nome
Alpha Cognition Inc
Settore
Industria
Telefono
(858) 344-4375
Indirizzo
1200-750 W PENDER ST, VANCOUVER
Confronta ACOG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACOG
Alpha Cognition Inc
|
8.65 | 119.03M | 0 | -14.72M | -7.41M | -2.83 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Alpha Cognition Inc Stock (ACOG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-18 | Iniziato | H.C. Wainwright | Buy |
Alpha Cognition Inc Borsa (ACOG) Ultime notizie
We Think Alpha Cognition (NASDAQ:ACOG) Can Easily Afford To Drive Business Growth - Yahoo Finance
Alpha Cognition Inc. Reports Strong Q1 2025 Performance - TipRanks
Alpha Cognition’s Earnings Call Highlights Success and Growth - TipRanks
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates - Nasdaq
Alpha Cognition Q1 2025 Earnings Call Transcript - MarketBeat
ALPHA COGNITION Earnings Results: $ACOG Reports Quarterly Earnings - Nasdaq
Alpha Cognition Inc. SEC 10-Q Report - TradingView
Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview - BioSpace
Alpha Cognition (ACOG) Expected to Announce Earnings on Tuesday - Defense World
Alpha Cognition, Inc.’s (NASDAQ:ACOG) Lock-Up Period To Expire on May 12th - Defense World
Will Alpha Cognition's Recently Launched Alzheimer's Drug Be A Commercial Success? - RTTNews
Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview - BioSpace
Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference - Yahoo Finance
(Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference - Business Wire
Alpha Cognition Inc. Reports Strong 2024 Financials - TipRanks
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens - BioSpace
Alpha Cognition announces board changes - Investing.com
Alpha Cognition announces board changes By Investing.com - Investing.com Canada
Alpha Cognition Appoints Robert Wills To Board - citybiz
Alpha Cognition Earnings Call: Positive Outlook Amid Growth - TipRanks
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China - The Globe and Mail
Alpha Cognition stock hits 52-week low at $4.65 amid downturn - Investing.com Canada
HC Wainwright Expects Stronger Earnings for Alpha Cognition - Defense World
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024 - TradingView
Alpha Cognition (NASDAQ:ACOG) Given Buy Rating at HC Wainwright - Defense World
Alpha Cognition Inc. (ACOG) reports earnings - Quartz
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview - Business Wire
Earnings Scheduled For March 31, 2025 - Benzinga
Comparing Alpha Cognition (ACOG) and The Competition - Defense World
Alpha Cognition (NASDAQ:ACOG) Upgraded at Raymond James - Defense World
Contrasting Alpha Cognition (NASDAQ:ACOG) & Cognition Therapeutics (NASDAQ:CGTX) - Defense World
Alpha Cognition (ACOG) Projected to Release Quarterly Earnings on Wednesday - Defense World
HC Wainwright Predicts Alpha Cognition Q1 Earnings - MarketBeat
Rosalind Advisors Inc. Invests $1.49 Million in Alpha Cognition, Inc. (NASDAQ:ACOG) - MarketBeat
Alpha Cognition (NASDAQ:ACOG) Now Covered by HC Wainwright - MarketBeat
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury - The Globe and Mail
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview - Business Wire
90% Workforce Reduction Sent This Small Cap Soaring - The Globe and Mail
Alpha Cognition Inc Azioni (ACOG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alpha Cognition Inc Azioni (ACOG) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MERTZ LEONARD POWELL | Director |
Nov 13 '24 |
Buy |
5.75 |
8,695 |
49,996 |
93,725 |
| HAVENS JOHN PRENTISS | Director |
Nov 13 '24 |
Buy |
5.75 |
4,347 |
24,995 |
273,272 |
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):